Xbrane Biopharma AB (publ) (STO: XBRANE)
Sweden
· Delayed Price · Currency is SEK 0.185
+0.004 (2.44%)
Nov 29, 2024, 5:29 PM CET
Xbrane Biopharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 199.81 | 238.73 | 57.62 | 10.71 | - | - | Upgrade
|
| Revenue | 199.81 | 238.73 | 57.62 | 10.71 | - | - | Upgrade
|
| Revenue Growth (YoY) | 5.64% | 314.33% | 438.03% | - | - | - | Upgrade
|
| Cost of Revenue | 76.19 | 203.34 | - | - | - | 18.27 | Upgrade
|
| Gross Profit | 123.62 | 35.39 | 57.62 | 10.71 | - | -18.27 | Upgrade
|
| Selling, General & Admin | 38.49 | 40.03 | 31.54 | 31.4 | 26.51 | 26.87 | Upgrade
|
| Research & Development | 355.51 | 305.78 | 199.65 | 160.62 | 197.28 | 137.67 | Upgrade
|
| Other Operating Expenses | -12.49 | -13.71 | -20.91 | -4.85 | -7.14 | -2.89 | Upgrade
|
| Operating Expenses | 381.51 | 332.11 | 210.27 | 187.17 | 216.65 | 161.64 | Upgrade
|
| Operating Income | -257.89 | -296.72 | -152.65 | -176.46 | -216.65 | -179.91 | Upgrade
|
| Interest Expense | -48.25 | -18.5 | -2.58 | -2.64 | -0.69 | -1.46 | Upgrade
|
| Interest & Investment Income | - | 2.41 | 0.3 | - | - | 0.05 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.43 | -9.15 | -13.56 | -4.13 | -0.79 | -6.66 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.06 | -0.06 | -0.01 | -0.01 | - | -0.01 | Upgrade
|
| Pretax Income | -304.77 | -322.03 | -168.51 | -183.23 | -218.13 | -187.99 | Upgrade
|
| Earnings From Continuing Operations | -304.77 | -322.03 | -168.51 | -183.23 | -218.13 | -187.99 | Upgrade
|
| Earnings From Discontinued Operations | -65.79 | -66.14 | -4 | -5.15 | -7.9 | - | Upgrade
|
| Net Income | -370.56 | -388.17 | -172.51 | -188.38 | -226.03 | -187.99 | Upgrade
|
| Net Income to Common | -370.56 | -388.17 | -172.51 | -188.38 | -226.03 | -187.99 | Upgrade
|
| Shares Outstanding (Basic) | 854 | 29 | 26 | 24 | 18 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 854 | 29 | 26 | 24 | 18 | 11 | Upgrade
|
| Shares Change (YoY) | 2952.35% | 12.26% | 8.38% | 30.25% | 61.86% | 80.09% | Upgrade
|
| EPS (Basic) | -0.43 | -13.52 | -6.75 | -7.98 | -12.48 | -16.80 | Upgrade
|
| EPS (Diluted) | -0.44 | -13.52 | -6.75 | -7.99 | -12.48 | -16.80 | Upgrade
|
| Free Cash Flow | -309.44 | -413.47 | -205.53 | -247.29 | -242.26 | -149.78 | Upgrade
|
| Free Cash Flow Per Share | -0.36 | -14.40 | -8.04 | -10.48 | -13.37 | -13.38 | Upgrade
|
| Gross Margin | 61.87% | 14.82% | 100.00% | 100.00% | - | - | Upgrade
|
| Operating Margin | -129.07% | -124.29% | -264.94% | -1647.74% | - | - | Upgrade
|
| Profit Margin | -185.46% | -162.60% | -299.41% | -1759.04% | - | - | Upgrade
|
| Free Cash Flow Margin | -154.87% | -173.20% | -356.72% | -2309.16% | - | - | Upgrade
|
| EBITDA | -246.75 | -287.62 | -145.21 | -171.93 | -214.07 | -178.04 | Upgrade
|
| EBITDA Margin | -123.49% | -120.48% | -252.03% | - | - | - | Upgrade
|
| D&A For EBITDA | 11.14 | 9.1 | 7.44 | 4.53 | 2.57 | 1.88 | Upgrade
|
| EBIT | -257.89 | -296.72 | -152.65 | -176.46 | -216.65 | -179.91 | Upgrade
|
| EBIT Margin | -129.07% | -124.29% | -264.94% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.